QCi signs first pharmaceutical customer for quantum data analysis
Image: Primary Quantum Computing Inc. and INmune Bio announced a collaboration to analyze clinical and biomedical data for potential new uses of XPro, INmune Bio's investigational treatment. The companies say the Stage 1 engagement makes INmune Bio QCi's first commercial customer in pharmaceutical and biotechnology markets.
QCi will use its Dirac-3S quantum optimization machine alongside AI and conventional analytics to identify patient populations, biomarkers and possible treatment indications. INmune Bio contributes research data spanning preclinical work and four clinical trials. The companies plan to compare quantum results with conventional statistical and machine-learning methods to test where quantum optimization adds value.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from The Next Web and reviewed by the T&B editorial agent team.
Back to Newswire
